This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Treatment for Presumed Ocular Histoplasmosis (HANDLE)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2014 by John Kitchens, MD, Retina Associates of Kentucky.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
John Kitchens, MD, Retina Associates of Kentucky Identifier:
First received: February 11, 2013
Last updated: June 13, 2014
Last verified: June 2014
The purpose of this study is to monitor safety outcomes for patients being treated with intravitreal aflibercept injections for choroidal neovascularization secondary to Presumed Ocular Histoplasmosis Syndrome.

Condition Intervention Phase
Ocular Histoplasmosis Drug: aflibercept Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Intravitreal Aflibercept Injection for the Treatment of cHoroidAl Neovascularization seconDary to Presumed ocuLar Histoplasmosis syndromE.(the HANDLE Study)

Resource links provided by NLM:

Further study details as provided by John Kitchens, MD, Retina Associates of Kentucky:

Primary Outcome Measures:
  • ocular and systemic adverse events [ Time Frame: through Month 12 ]
    The primary objective of the study is the incidence and severity of ocular and systemic adverse events through Month 12

Secondary Outcome Measures:
  • Visual acuity [ Time Frame: Months 3, 6, 9 and 12 ]
    • Mean change in BCVA from Baseline
    • Proportion of subjects gaining >5,10 and 15 letters
    • Proportion of subjects losing >5, 10 and 15 letters

Other Outcome Measures:
  • OCT changes [ Time Frame: baseline to 12 months ]
    Mean change from baseline in central subfield thickness over time up to 12 months assessed on OCT

Estimated Enrollment: 40
Study Start Date: March 2013
Estimated Study Completion Date: August 2014
Estimated Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: intravitreal aflibercept injection

Group A -Monthly intravitreal aflibercept injection for 3 months (Baseline, Months 1 and 2), then mandatory every 2 months intravitreal aflibercept injection (Months 4,6, 8 and 10)for 12 months. Monthly visits with evaluations for as needed intravitreal aflibercept injection.

Drug: aflibercept
Experimental: intravitreal aflibercept
Group B- One intravitreal aflibercept injection at Baseline, then monthly visits with evaluations for as needed dosing of intravitreal aflibercept injection for 12 months.
Drug: aflibercept


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Active choroidal neovascularization (CNV) secondary to presumed ocular histoplasmosis demonstrated by active leakage on fluorescein angiography with spectal domain OCT evidence of subretinal or intraretinal fluid or PED.
  • Active CNV may also be defined as demonstrating active subretinal hemorrhage.
  • ETDRS Best corrected visual acuity 20/20-20/320.
  • willing and able to comply with all study clinic visits and study related procedures.
  • Willing to use and practice more than one form of contraceptives during the 13 month study for male and female.
  • Provide signed informed consent
  • Able to understand and complete study related questionnaires

Exclusion Criteria:

  • Under 18 years of age
  • CNV due to other causes than Presumed Ocular Histoplasmosis
  • Previous treatment in the study eye within 6 months prior to Day 1
  • More than 5 Intravitreal injections of anti-VEGF therapy within previous 12 months
  • Any clinical evidence of any other ocular condition other than Ocular histoplasmosis
  • History of allergy to fluorescein
  • Pregnant( or planning on becoming pregnant within the next 13 months) or breast feeding women
  • Sexually Active Men or Women who are NOT willing to practice more than one form of contraceptives during the next 13 months.
  • Anticipated or previous (within previous 3 months) systemic anti-VEGF therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01790893

Contact: Diana Holcomb, COA 859-264-2905

United States, Georgia
Southeast Retina Recruiting
Augusta, Georgia, United States, 30909
Contact: Jared Gardner    706-650-0061   
Contact: Courtney Caulder    706-650-0061   
Principal Investigator: Dennis Marcus, MD         
Sub-Investigator: Harinderjit Singh, MD         
United States, Kentucky
Retina Associates of Kentucky Recruiting
Lexington, Kentucky, United States, 40509
Contact: Diana Holcomb    859-264-2905   
Principal Investigator: John W. Kitchens, MD         
Sub-Investigator: William J Wood, MD         
Sub-Investigator: Tom Stone, MD         
Sub-Investigator: Rick Isernhagen, MD         
Sub-Investigator: Andrew Moshfeghi, MD         
United States, Ohio
Cincinnati Eye Institute Recruiting
Cincinnati, Ohio, United States, 45242
Contact: Megan Kingdon    513-569-3669      
Principal Investigator: Daniel Miller, MD         
Sub-Investigator: Michael Petersen, MD, PhD         
Sub-Investigator: Robert Sisk, MD         
Sub-Investigator: Robert Foster, MD         
Sub-Investigator: Christopher Riemann, MD         
Sub-Investigator: Brian Toussaint, MD         
Sponsors and Collaborators
John Kitchens, MD
Principal Investigator: John W Kitchens, MD Retina Associates of Kentucky
  More Information

Additional Information:
Responsible Party: John Kitchens, MD, Sponsor-Investigator, Retina Associates of Kentucky Identifier: NCT01790893     History of Changes
Other Study ID Numbers: IND 117497
Study First Received: February 11, 2013
Last Updated: June 13, 2014

Keywords provided by John Kitchens, MD, Retina Associates of Kentucky:

Additional relevant MeSH terms:
Choroidal Neovascularization
Choroid Diseases
Uveal Diseases
Eye Diseases
Neovascularization, Pathologic
Pathologic Processes
Mycoses processed this record on June 23, 2017